# Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma

> **NCT04910126** · PHASE2 · UNKNOWN · sponsor: **Union Hospital, Tongji Medical College, Huazhong University of Science and Technology** · enrollment: 84 (estimated)

## Conditions studied

- Soft Tissue Sarcoma
- Neoplasms, Connective and Soft Tissue
- Sarcoma Metastatic
- Sarcoma,Soft Tissue

## Interventions

- **DRUG:** Camrelizumab
- **DRUG:** Adriamycin

## Key facts

- **NCT ID:** NCT04910126
- **Lead sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-12
- **Primary completion:** 2023-01-12
- **Final completion:** 2023-11-12
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2021-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04910126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04910126, "Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04910126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*